San Diego-primarily based Viking Therapeutics marked itself as a significant competitor inside the weight loss drug market place in February just after revealing promising knowledge from the mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March